AstraZeneca PLC (AZNCF)
OTCMKTS · Delayed Price · Currency is USD
169.85
-2.25 (-1.31%)
Oct 9, 2025, 3:54 PM EDT
AstraZeneca Revenue
AstraZeneca had revenue of $14.46B in the quarter ending June 30, 2025, with 11.74% growth. This brings the company's revenue in the last twelve months to $56.50B, up 15.00% year-over-year. In the year 2024, AstraZeneca had annual revenue of $54.07B with 18.03% growth.
Revenue (ttm)
56.50B
Revenue Growth
+15.00%
P/S Ratio
4.72
Revenue / Employee
599.16K
Employees
94,300
Market Cap
266.87B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 54.07B | 8.26B | 18.03% |
| Dec 31, 2023 | 45.81B | 1.46B | 3.29% |
| Dec 31, 2022 | 44.35B | 6.93B | 18.53% |
| Dec 31, 2021 | 37.42B | 10.80B | 40.58% |
| Dec 31, 2020 | 26.62B | 2.23B | 9.16% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Elite Pharmaceuticals | 105.45M |
| Glass House Brands | 221.55M |
| Veradigm | 588.02M |
| Northwest Biotherapeutics | 1.09M |
| American Oncology Network | 1.76B |
| Silence Therapeutics | 27.17M |
| Jushi Holdings | 256.36M |
| AMJ Global Technology | 39.00 |
AstraZeneca News
- 16 hours ago - Collaboration Between Turbine and AstraZeneca (AZN) Enhances ADC Discovery - GuruFocus
- 16 hours ago - AstraZeneca (AZN) Unaffected by Potential Tariffs on Generic Drugs - GuruFocus
- 18 hours ago - Turbine Launches Collaboration with AstraZeneca, Leveraging Turbine's Virtual Disease Models to Rationalize ADC Discovery - PRNewsWire
- 1 day ago - AstraZeneca's Baxdrostat Meets Goal in Resistant Hypertension Study - Nasdaq
- 2 days ago - AstraZeneca (AZN) Reports Success in Phase 3 Hypertension Trial - GuruFocus
- 2 days ago - AZN: Baxdrostat Shows Promising Results in Phase III Trial - GuruFocus
- 2 days ago - AstraZeneca succeeds in late-stage trial for blood pressure therapy - Seeking Alpha
- 2 days ago - Baxdrostat met the primary endpoint in Bax24 Phase III trial in patients with resistant hypertension - Business Wire